ADIL

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.

Wall Street analysts forecast ADIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADIL is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Adial Pharmaceuticals Inc revenue for the last quarter amounts to -1.76M USD, decreased -20.23 % YoY.

Adial Pharmaceuticals Inc. EPS for the last quarter amounts to -1833373.00 USD, decreased % YoY.

Adial Pharmaceuticals Inc (ADIL) has 5 emplpoyees as of December 15 2025.

Today ADIL has the market capitalization of 7.09M USD.